INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Narrative review / 2014

Current clinical evidence for a therapeutic effect of high-dose intravenous vitamin C in cancer treatment is ambiguous.

This review evaluated the history and evidence surrounding high-dose intravenous (IV) vitamin C as an anticancer agent. Early reports claimed survival benefits, but subsequent oral randomized controlled trials showed no significant benefit, though pharmacokinetics differ substantially between oral and IV routes. In vitro data show vitamin C may act as a pro-oxidant at high concentrations, but clinical evidence remains ambiguous and largely limited to case series with poor correlation between plasma concentrations and response. Consequently, high-dose IV vitamin C cannot currently be recommended outside of a clinical trial.

Study type
Narrative review
Who was studied
Patients with cancer
What was measured
Anticancer therapeutic efficacy and survival benefit

THE PAPER

Review of high-dose intravenous vitamin C as an anticancer agent.

Wilson MK, Baguley BC, Wall C, Jameson MB, Findlay MP. Asia Pac J Clin Oncol, 2014.

PubMed 24571058 ↗DOI 10.1111/ajco.12173 ↗

CancerNutrients & adequacy

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.